CIITA Antibody (E-12): sc-376174

CIITA Antibody (E-12) is a mouse monoclonal IgG1 antibody that detects CIITA in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CIITA, or class II transactivator, plays a crucial role in the immune response by regulating the expression of major histocompatibility complex (MHC) class II molecules, which are essential for presenting antigens to CD4+ T cells. This process is vital for the activation of T cells and the subsequent adaptive immune response. CIITA functions as a coactivator for MHC class II-specific gene expression and is involved in the negative regulation of the IL-4 gene promoter during T cell differentiation. CIITA′s activity is influenced by GTP-binding and acidic, proline-serine-threonine-rich regions, which are necessary for function. Additionally, CIITA interacts with other proteins, such as RFX-B, which is a key component of the RFX complex required for MHC class II transcription. Defects in CIITA can lead to severe immunodeficiencies, including Bare Lymphocyte Syndrome, highlighting the importance of CIITA in maintaining a functional immune system. Anti-CIITA antibody (E-12) is an invaluable tool for researchers studying immune responses and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CIITA Antibody (E-12) References:

1. The dual function of the MHC class II transactivator CIITA against HTLV retroviruses.  |  Tosi, G., et al. 2009. Front Biosci (Landmark Ed). 14: 4149-56. PMID: 19273341
2. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.  |  Forlani, G., et al. 2016. J Transl Med. 14: 94. PMID: 27089879
3. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.  |  Accolla, RS., et al. 2019. Front Immunol. 10: 1806. PMID: 31417570
4. Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells.  |  Forlani, G., et al. 2020. Cancers (Basel). 12: PMID: 33138029
5. BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II.  |  Redelman-Sidi, G., et al. 2022. Cancer Immunol Res. 10: 1241-1253. PMID: 36040405
6. CIITA promoter polymorphism impairs monocytes HLA-DR expression in patients with septic shock.  |  Miatello, J., et al. 2022. iScience. 25: 105291. PMID: 36304101
7. NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity.  |  Santharam, MA., et al. 2023. Int J Mol Sci. 24: PMID: 37108368
8. IL-27p28 specifically regulates MHC II expression in macrophages through CIITA.  |  Han, Y., et al. 2023. Immunobiology. 228: 152757. PMID: 37944428
9. NLRP3 regulates CIITA/MHC II axis and interferon-γ-inducible chemokines in Malassezia globosa-infected keratinocytes.  |  Luo, Y., et al. 2024. Mycoses. 67: e13680. PMID: 38214420
10. Adenoviral delivery of the CIITA transgene induces T-cell-mediated killing in glioblastoma organoids.  |  Salvato, I., et al. 2024. Mol Oncol.. PMID: 39535369

The preferred CIITA antibody is CIITA Antibody (7-1H): sc-13556.